Bioavailability, metabolism and physiological impact of 4-oxo-flavonoids

Nutrition Research

Volumn 16, Issue 3, 1996, Pages 517-544

  Manach, Claudine ^a   Regerat, Françoise ^b   Texier, Odile ^b   Agullo, Georgine ^a   Demigne, Christian ^a   Remesy, Christian ^a  

^a CEMAGREF   (France)

^b UNIVERSITÉ CLERMONT AUVERGNE   (France)

Author keywords

4 oxo flavonoids; antioxidant; antitumoral effect; carcinogenicity; cardiovascular diseases; quercetin

Indexed keywords

APIGENIN; BAICALEIN; DAIDZEIN; DIOSMETIN; FISETIN; FLAVONOID; GENISTEIN; HESPERETIN; KAEMPFEROL; LIQUIRITIGENIN; LUTEOLIN; MORIN; MYRICETIN; NARINGENIN; QUERCETIN; TAXIFOLIN;

ANTINEOPLASTIC ACTIVITY; CANCER PREVENTION; CARDIOVASCULAR DISEASE; FEEDING BEHAVIOR; FOOD COMPOSITION; FRUIT; LIPID PEROXIDATION; PRIORITY JOURNAL; REVIEW; VEGETABLE;

EID: 0029914983     PISSN: 02715317     EISSN: None     Source Type: Journal    
DOI: 10.1016/0271-5317(96)00032-2     Document Type: Review

References (180)

1. Geiger H. Biflavonoids and triflavonoids. In: Harborne JB, ed. The Flavonoids: Advances in research since 1986. London: Chapman & Hall, 1993: 95-115.
2. Wollenweber E. Flavones and flavonols. In: Harborne JB, ed. The Flavonoids: Advances in research since 1986. London: Chapman & Hall, 1993: 259-335.
3. Williams CA, Harborne JB. Flavone and flavonol glycosides. In: Harborne JB, ed. The Flavonoids: Advances in research since 1986. London: Chapman & Hall, 1993: 337-85.
4. Kühnau J. The flavonoids. A class of semi-essential food components: Their role in human nutrition. World Rev. Nutr. Diet 1976; 24:117-91.
5. Hertog MGL, Feskens EJM, Hollman PCH, Katan MB, Kromhout D. Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. Lancet 1993a; 342:1007-11.
6. Herrmann K. Flavonols and flavones in food plants: a review. J. Food Technol. 1976; 11:433-48.
7. Franke AA, Custer LJ, Cerna CM, Narala KK. Quantitation of phytoestrogens in legumes by HPLC. J. Agric. Food Chem. 1994; 42:1905-13.
8. Hertog MGL, Hollman PCH, Katan MB. Content of potentially anticarcinogenic flavonoids of 28 vegetables and 9 fruits commonly consumed in the Netherlands. J. Agric. Food Chem. 1992; 40:2379-83.
9. Hertog MGL, Hollman PCH, van der Putte B. Content of potentially anticarcinogenic flavonoids of tea infusions, wines, and fruits juices. J. Agric. Food Chem. 1993b; 41:1242-6.
10. Manach C, Morand C, Texier O, Favier ML, Agullo G, Demigne C, Regerat F, Remesy C. Quercetin metabolites are found in noticeable concentration in plasma of rats fed rutin or quercetin diets. J.Nutr. 1995; in press.
11. Bokkenheuser VD, Shackleton CHL, Winter J. Hydrolysis of dietary flavonoid glycosides by strains of intestinal Bacteroides from humans. Biochem. J. 1987; 248:953-6.
12. MacDonald IA, Mader JA, Bussard RG. The role of rutin and quercetrin in stimulating flavonol glycosidase activity by cultured cell-free microbial preparations of human feces and saliva. Mutat. Res. 1983; 122:95-102.
13. Hackett AM. The metabolism of flavonoid compounds in mammals. In: Cody V, Middleton E, Harborne JB, eds. Plant Flavonoids in Biology and Medicine. Biochemical Pharmacological and Structure Activity Relationships. New York: Alan R. Liss, Inc., 1986: 177-94.
14. Griffiths LA, Barrow A. Metabolism of flavonoid compounds in germ-free rats. Biochem. J. 1972; 130:1161-2.
15. Booth AN, Murray CW, Jones FT, DeEds F. The metabolic fate of rutin and quercetin in the animal body. J. Biol. Chem. 1956; 233:251-7.
16. Griffiths LA, Smith GE Metabolism of apigenin and related compounds in the rat Metabolic formation in vivo and by the intestinal microflora in vitro. Biochem. J. 1972; 128:901-11.
17. 14C] quercetin in the ACI rat. Japan J. Exp. Med. 1983; 53:41-50.
18. Gugler R, Leschik M, Dengler HJ. Disposition of quercetin in man after single oral and intravenous doses. Europ. J. Clin. Pharmacol. 1975; 9:229-34:
19. Xu X, Wang HJ, Murphy PA, Cook L, Hendrich S. Daidzein is a more bioavailable soymilk isoflavone than is genistein in adult women. J. Nutr. 1994; 124:825-32.
20. Setchell KDR. Effects of lignans and other dietary estrogens. In: Kritchevsky D., Bonfield C., eds. Dietary fiber in health and disease. St Paul, Minnesota, USA: Eagan press, 1995: 294-304.
21. Kelly GE, Joannou GE, Reeder AY, Nelson C, Waring MA. The variable metabolic response to dietary isoflavones in humans. Proc. Soc. Exp. Biol. Med. 1995; 208:40-3.
22. Shimamura H, Susuki H, Hanano M, Susuki A, Sugiyama Y. Identification of tissues responsible for the conjugative metabolism of liquiritigenin in rats: an analysis based on metabolite kinetics. Biol. Pharm. Bull. 1993; 16:899-907.
23. Zhu BT, Ezell EL, Liehr JG. Catechol-O-methyltransferase-catalysed rapid O-methylation of mutagenic flavonoids. J. Biol. Chem. 1994; 1:292-9.
24. Halliwell B. Oxidants and human disease: some new concepts: FASEB J. 1987; 1:358-64.
25. Bors W, Saran M. Radical scavenging by flavonoid antioxydants. Free Rad. Res. Comms. 1987; 2:289-94.
26. Bors W, Heller W, Michel C, Saran M. Flavonoids as antioxidants: determination of radical-scavenging efficiencies. Methods Enzymol. 1990; 186:343-55.
27. Robak J, Gryglewski RJ. Flavonoids are scavengers of superoxide anion. Biochem. Pharmacol. 1988; 37:837-41.
28. Afanas'ev IB, Dorozhko AI, Brodskii AV, Kostyuk VA, Potapovitch AI. Chelating and free radical scavenging mechanisms of inhibitory action of rutin and quercetin in lipid peroxidation. Biochem. Pharmacol. 1989; 38:1763-9.
29. Ueno I, Kohno M, Haraikawa K, Hirono I. Interaction between quercetin and superoxide radicals. Reduction of the quercetin mutagenicity. J. Pharm. Dyn. 1984 7:798-803.
30. 2°-. Free Radic. Biol. Med. 1991; 11:1-8.
31. g) quenching. J. Photochem. Photobiol. B. 1993; 19:205-15.
32. Thompson M, Williams CR. Stability of flavonoid complexes of copper(II) and flavonoid antioxidant activity. Anal. Chim. Acta 1976; 85:375-81.
33. Laughton MJ, Halliwell B, Evans PJ, Hoult JR. Antioxidant and pro-oxidant actions of the plant phenolics quercetin, gossypol and myricetin. Effects on lipid peroxidation, hydroxyl radical generation and bleomycin-dependent damage to DNA. Biochem. Pharmacol. 1989; 38:2859-65.
34. Hodnick WF, Kung FS, Roettger WJ, Bohmont CW, Pardini RS. Inhibition of mitochondrial respiration and production of toxic oxygen radicals by flavonoids. Biochem. Pharmacol. 1986; 35:2345-57.
35. Canada AT, Giannella E, Nguyen TD, Mason RP. The production of reactive oxygen species by dietary flavonols. Free Radic. Biol. Med. 1990; 9:441-9.
36. Bruckdorfer KR. Non-enzymatic oxidation of lipids and lipoproteins: the role of metals and nitric oxide. Curr. Opin. Lipidol. 1993; 4:238-43.
37. Witzum JL, Steinberg D. Role of oxidized Low Density Lipoprotein in atherogenesis. J. Clin. Invest. 1991; 88:1785-92.
38. Rankin SM, Parthasarathy S, Steinberg D. Evidence for a dominant role of lipoxygenase(s) in the oxidation of LDL by mouse peritoneal macrophages. J. Lipid Res. 1991; 32:449-56.
39. Ylä-Herttuala S, Rosenfeld ME, Parthasarathy S, Glass CK, Sigal E, Witzum JL, Steinberg D. Colocalization of 15-lipoxygenase mRNA and protein with epitopes of oxidized low density lipoprotein in macrophage-rich areas of atherosclerotic lesions. Proc. Natl. Acad. Sci. USA 1990; 87:6959-63.
40. Gryglewski RJ, Korbut R, Robak j, Swies J. On the mechanism of antithrombotic action of flavonoids. Biochem. Pharmacol. 1987; 36:317-22.
41. Carew TE, Schwenke DC, Steinberg D. Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty steaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipemic rabbit. Proc. Natl. Acad. Sci. USA 1987; 84:7725-9.
42. De Whalley CV, Rankin SM, Hoult JRS, Jessup W & Leake DS. Flavonoids inhibit the oxidative modification of low density lipoproteins by macrophages. Biochem. Pharmacol. 1990; 39:1743-50.
43. Frankel EN, Kanner J, German JB, Parks E, Kinsella JE. Inhibition of oxidation of human low-density lipoprotein by phenolic substances in red wine. Lancet 1993; 341:454-7.
44. Maxwell S, Cruickshank A, Thorpe G. Red wine and antioxidant activity in serum. Lancet 1994; 344:193-4.
45. Kondo K, Matsumoto A, Kurata H, Tanahashi H, Koda H, Amachi T, Itakura H. Inhibition of oxidation of low-density lipoprotein with red wine. Lancet 1994; 344:1152.
46. Fuhrman B, Lavy A, Aviram M. Consumption of red wine with meals reduces the susceptibility of human plasma and low-density lipoprotein to lipid peroxidation. Am. J. Clin. Nutr. 1995; 61:549-54.
47. Nègre-Salvayre A, Salvayre R. Quercetin prevents the cytotoxicity of oxidized LDL on lymphoid cell lines. Free Radic. Biol. Med. 1992; 12:101-6.
48. Huang HC, Wang HR, Hsieh LM. Antiproliferative effect of baicalein, a flavonoid from a Chinese herb, on vascular smooth muscle cell. Eur. J. Pharmacol. 1994; 251:91-3.
49. Aviram M. Platelets and the arterial wal lesion. Curr. Opin. Lipidol. 1992; 3:344-48.
50. Tzeng SH, Ko WC, Ko FN, Teng CM. Inhibition of platelet aggregation by some flavonoids. Thromb. Res. 1991; 64:91-100.
51. Beretz A, Anton R, Cazenave JP. The effects of flavonoids on cyclic nucleotide phosphodiesterases. In: Cody V, Middleton E, Harborne JB, eds. Plant Flavonoids in Biology and Medicine. Biochemical Pharmacological and Structure Activity Relationships. New York: Alan R. Liss, Inc., 1986: 281-96.
52. Beretz A, Stierle A, Anton R, Cazenave J.P. Role oi cyclic AMP in the inhibition of human platelet aggregation by quercetin, a flavonoid that potentiates the effect of prostacyclin. Biochem. Pharmacol. 1981 ;31:3597-3600.
53. Nakashima S, Koike T, Nozawa Y. Genistein, a protein tyrosine kinase inhibitor, inhibits thromboxane A2-mediated human platelet responses. Mol. pharmacol. 1991; 39:475-80.
54. Ozaki Y, Yatomi Y, Jinnai Y, Kume S. Effects of genistein, a tyrosine kinase inhibitor, on platelet functions. Biochem. Pharmacol. 1993; 46:395-403.
55. Murphy CT, Kellie S, Westwick J. Tyrosine-kinase activity in rabbit platelets stimulated with platelet-activating factor. The effect of inhibiting tyrosine kinase with genistein on platelet-signal-molecule elevation anf functional responses. Eur. J. Biochem. 1993; 216:639-51.
56. Kato N, Tosa N, Doudou T, Imamura T. Effects of dietary quercetin on serum lipids. Agric. Biol. Chem. 1983a; 47:2119-20.
57. Basarkar PW. Cholesterol lowering action of vitamin P-like compounds in rats. Indian J. Exp. Biol. 1981; 19:787-9.
58. Borchardt RT, Huber JA. Catechol O-methyltransferase. 5. Structure-Activity relationships for inhibition by flavonoids. J. Med. Chem. 1975; 18:120-2.
59. Kuppusamy UR, Khoo HE, Das NP. Structure-activity studies of flavonoids as inhibitors of hyaluronidase. Biochem. Pharmacol. 1990; 40:397-401.
60. Régnault-Roger C. Vitamin P, Bioflavonoides ou facteur C2: réévaluation d'un concept. Cah. Nutr. Diet. 1986; XXI:359-68.
61. Brown JP. A review of the genetic effects of naturally occuring flavonoids, anthraquinones and related compounds. Mutat. Res. 1980; 75:243-77.
62. Watson WAF. The mutagenic activity of quercetin and kaempferol in Drosophila melanogaster. Mutat. Res. 1982; 103:145-7.
63. Yoshida MA, Sasaki M, Sugimura K, Kawachi T. Cytogenetic effects of quercetin on cultured mammalian cells. Proc. Japan Acad. 1980; 56:443-7.
64. Carver JH, Carrano AV, MacGregor JT. Genetic effects of the flavonols quercetin, kaempferol, and galangin on Chinese hamster ovary cells in vitro. Mutat. Res. 1983; 113:45-60.
65. +/- mutation, DNA single-strand break and BALB/c 3T3 chemical transformation assays. Mutat. Res. 1981; 88:317-24.
66. Van der Hoeven JCM, Bruggeman IM, Debets FMH. Genotóxicity of quercetin in cultured mammalian cells. Mutat. Res. 1984; 136:9-21.
67. Umezawa K, Matsushima T, Sugimura T, Hirakawa T, Tanaka M, Katoh Y, Takayama S. In vitro transformation of hamster embryo cells by quercetin. Toxicol. Lett. 1977; 1:175-8.
68. Sakai A, Sasaki K, Mizusawa H, Ishidate M. Effects of quercetin, a plant flavonol, on the two-stage transformation in vitro. Teratogen. Carcinogen. Mutagen. 1990; 10:333-40.
69. Sahu RK, Basu R, Sharma A. Genetic toxicological testing of some plant flavonoids by the micronucleus test. Mutat. Res. 1981; 89:69-74.
70. MacGregor JT. Mutagenicity studies of flavonoids in vivo and in vitro. Toxicol. Appl. Pharmacol. 1979; 48:A47. (Abstract).
71. Pamukcu AM, Yalciner S, Hatcher JF, Bryan GT. Quercetin, a rat intestinal and bladder carcinogen present in bracken fern (Pteridium aquilinum). Cancer Res. 1980; 40:3468-72.
72. Dunnick JK, Hailey JR. Toxicity and carcinogenicity studies of quercetin, a natural component of foods. Fundam. Appl. Toxicol. 1992; 19:423-31.
73. Ito N. Is quercetin carcinogenic? Jpn.J. Cancer Res. 1992; 83:312-4.
74. Saito D, Shirai A, Matsushima T, Sugimura T, Hirono I. Test of carcinogenicity of quercetin, a widely distributed mutagen in food. Teratogenesis Carcinogen. Mutagen. 1980; 1:213-21.
75. Hirono I, Ueno I, Hosaka S, Takanashi H, Matsushima T, Sugimura T, Natori S. Carcinogenicity examination of quercetin and rutin in ACI rats. Cancer Lett. 1981; 13:15-21.
76. Takanashi H, Aiso S, Hirono I. Carcinogenicity test of quercetin and kaempferol in rats by oral administration. J. Food Safety 1983; 5:55-60.
77. Ito N, Hagiwara A, Tamano S, Kagawa M, Shibata MA, Kurata Y, Fukushima S. Lack of carcinogenicity of quercetin in F344/DuCrj rats. Jpn. J. Cancer Res. 1989; 80:317-25.
78. Morino K, Matsukura N, Kawachi T, Ohgaki H, Sugimura T, Hirono I. Carcinogenicity test of quercetin and rutin in golden hamsters by oral administration. Carcinogenesis 1982; 3:93-7.
79. Rahman A, Fazal F, Greensill J, Ainley K, Parish JH, Hadi SM. Strand scission in DNA induced by dietary flavonoids: role of Cu(I) and oxygen free radicals and biological consequences of scission. Mol. Cell. Biochem. 1992; 111:3-9.
80. Rueff J, Laires A, Gaspar J, Borba H, Rodrigues A. Oxygen species and the genotoxicity of quercetin. Mutat. Res. 1992; 265:75-81.
81. Birt DF, Bresnick E. Chemoprevention by nonnutrient components of vegetables and fruits. In Alfin-Slater RB., Kritchevsky D., eds. Cancer and Nutrition. New York: Plenum Press, 1991: 221-260.
82. Yamashita Y, Kawada S, Nakano H. Induction of mammalian topoisomerase II dependent DNA cleavage by nonintercalative flavonoids, genistein and orobol. Biochem Pharmacol. 1990; 39:737-44.
83. Austin CA, Patel S, Ono K, Nakane H, Fisher LM. Site-specific DNA cleavage by mammalian DNA topoisomerase II induced by novel flavone and catechin derivatives. Biochem J. 1992; 282:883-9.
84. Liu LF. DNA Topoisomerase poisons as antitumor drugs. Annu. Rev. Biochem. 1989; 58:351-75.
85. Wood AW, Smith DS, Chang RL, Huang MT, Conney AH. Effects of flavonoids on the metabolism of xenobiotics. In: Cody V, Middleton E, Harborne JB, eds. Plant Flavonoids in Biology and Medicine. Biochemical Pharmacological and Structure Activity Relationships. New York: Alan R. Liss, Inc., 1986: 195-210.
86. Huang MT, Johnson EF, Muller-Eberhard U, Koop DR, Coon MJ, Conney AH. Specificity in the activation and inhibition by flavonoids of benzo[α]pyrene hydroxylation by cytochrome P-450 isozymes from rabbit liver microsomes. J. Biol. Chem. 1981a; 256:10897-901.
87. Huang MT, Chang RL, Fortner JG, Conney AH. Studies on the mechanism of activation of microsomal benzo[α]pyrene hydroxylation by flavonoids. J. Biol. Chem. 1981b; 256: 6829-36.
88. Lasker JM, Huang MT, Conney AH. In vitro and in vivo activation of oxidative drug metabolism by flavonoids. J. Pharmacol. Exp. Ther. 1984; 229:162-70.
89. Tsyrlov IB, Mikhailenko VM, Gelboin HV. Isozyme-and species-specific susceptibility of cDNA-expressed CYP1A P-450 to different flavonoids. Biochim. Biophys. Acta 1994; 1205:325-35.
90. Chae YH, Marcus CB, Ho DK, Cassady JM, Baird WM. Effects of synthetic and naturally occurring flavonoids on benzo[α]pyrene metabolism by hepatic microsomes prepared from rats treated with cytochrome P-450 inducers. Cancer Lett. 1991; 60:15-24.
91. Buening MK, Chang RL, Huang MT, Fortner JG, Wood AW, Conney AH. Activation and inhibition of benzo(a)pyrene and afltoxin B1 metabolism in human liver microsomes by naturally occuring flavonoids. Cancer Res. 1981; 41:67-72.
92. Merlos M, Sanchez RM, Camarasa J, Adzet T. Flavonoids as inhibitors of rat liver cytosolic glutathione S-transferase. Experientia 1991; 47:616-9.
93. Iio M, Kawaguchi H, Sakota Y, Otonari J, Nitahara H. Effects of polyphenols, including flavonoids, on glutathione S-transférase and glutathione reductase. Biosci. Biotech. Biochem. 1993; 57:1678-80.
94. Trela BA, Carlson GP. Effect of flavanone on mixed-function oxidase and conjugaison reactions in rats. Xenobiotica 1987; 17:11-6.
95. Siess MH, Le Bon AM, Suschetet M. Dietary modification of drug-metabolizing enzyme activities: dose-response effect of flavonoids. J. Toxicol. Environ. Health 1992; 35:141-52.
96. Siess MH, Guillermic M, Le Bon AM, Suschetet M. Induction of monooxygenase and tranferase activities in rat by dietary administration of flavonoids. Xenobiotica 1989b; 19:1379-86.
97. Nijhoff WA, Groen GM, Peters WHM. Induction of rat hepatic and intestinal glutathione S-transferases and glutathione by dietary naturally occurring anticarcinogens. Int. J. Oncology 1993; 3:1131-9.
98. Das M, Singh SV, Mukhtar H, Awasthi YC. Differential inhibition of rat and human glutathione S-transferase isoenzymes by plant phenols. Biochem. Biophys. Res. Commun. 1986; 141:1170-6.
99. Huang MT, Wood AW, Newmark HL, Sayer JM, Yagi H, Jerina DM, Conney AH. Inhibition of the mutagenicity of bay-region diol-epoxides of polycyclic aromatic hydrocarbons by phenolic plant flavonoids. Carcinogenesis 1983; 4:1631-7.
100. Wargovitch MJ, Newmark HL. Inability of several mutagen-blocking agents to inhibit 1,2-dimethylhydrazine-induced DNA-damaging activity in colonic epithelium. Mutat. Res. 1983; 121:77-80.
101. Wargovitch MJ, Eng VWS, Newmark HL. Inhibition by plant phenols of benzo[a]pyrene-induced nuclear aberrations in mammalian intestinal cells: a rapid in vivo assessment method. Food Chem. Toxicol. 1985; 23:47-9.
102. Endicott JA, Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu. Rev. Biochem. 1989; 58:137-71.
103. Kioka N, Hosokawa N, Komano T, Hirayoshi K, Nagata K, Ueda K. Quercetin, a bioflavonoid, inhibits the increase of human multidrug resistance gene (MDR1) expression caused by arsenite. FEBS Lett. 1992; 301:307-9.
104. Phang JM, Poore CM, Lopaczynska J, Yeh GC. Flavonol-stimulated efflux of 7,12-dimethylbenz(a)anthracene in multidrug-resistant breast cancer cells. Cancer Res. 1993; 53:5977-81.
105. Critchfield JW, Welsh CJ, Phang JM, Yeh GC. Modulation of adriamycin accumulation and efflux by flavonoids in HCT-15 colon cells. Biochem. Pharmacol. 1994; 48:1437-45.
106. Le Bon AM, Siess MH, Suschetet M. Inhibition of microsome-mediated binding of benzo[α]pyrene to DNA by flavonoids either in vitro or after dietary administration to rats. Chem.-Biol. Interact. 1992; 83:65-71.
107. Das M, Khan WA, Asokan P, Bickers DR, Mukhtar H. Inhibition of polycyclic aromatic Hydrocarbon-DNA adduct formation in epidermis and lungs of SENCAR mice by naturally occurring plant phenols. Cancer Res. 1987b; 47:767-73.
108. Stavric B, Matula I. Flavonoids in foods: their significance for nutrition and health. In: Packer L, Ong ASH, eds. Lipid-soluble antioxidants: biochemistry and clinical applications. Birkhäuser Verlag, Basel, Switzerland, 1992: 274-94.
109. Deschner EE, Ruperto J, Wong G, Newmark HL. Quercetin and rutin as inhibitors of azoxymethanol-induced colonic neoplasia. Carcinogenesis 1991; 12:1193-6.
110. Deschner EE, Ruperto JF, Wong GY, Newmark HL. The effect of dietary quercetin and rutin on AOM-induced acute colonic epithelial abnormalities in mice fed a high-fat diet. Nutr. Cancer 1993; 20:199-204.
111. Verma AK, Johnson JA, Gould MN, Tanner MA. Inhibition of 7,12-dimethylbenz(a)anthracene-and N-nitrosomethylurea-induced rat mammary cancer by dietary flavonol quercetin. Cancer Res. 1988; 48:5754-8.
112. Kato R, Nakadate T, Yamamoto S, SugimuraT. Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced tumor promotion and ornithine decarboxylase activity by quercetin: possible involvement of lipoxygenase inhibition. Carcinogenesis 1983b; 4:1301-5.
113. Wei H, Tye L, Bresnick E, Birt DF. Inhibitory effect of apigenin, a plant flavonoid, on epidermal ornithine decarboxylase and skin tumor promotion in mice. Cancer Res. 1990; 50:499-502.
114. Fujiki H, Horiuchi T, Yamashita K, Hakii H, Suganuma M, Nishino H, Iwashima A, Hirata Y, Sugimura T. Inhibition of tumor promotion by flavonoids. In: Cody V, Middleton E, Harborne JB, eds. Plant Flavonoids in Biology and Medicine. Biochemical Pharmacological and Structure Activity Relationships. New York: Alan R. Liss, Inc., 1986: 429-40.
115. Nishino H, Nagao M, Fujiki H, Sugimura T. Role of flavonoids in suppressing the enhancement of phospholipid metabolism by tumor promoters. Cancer Lett. 1983; 21:1-8.
116. 2+-calmodulin complex: possible mechanism for anti-tumor-promoting action of the flavonoid. Gann. 1984; 74:311-16.
117. Wei H, Bowen R, Cai Q, Barnes S, Wang Y. Antioxidant and antipromotional effects of the soybean isoflavone genistein. Proc. Soc. Exp. Biol. Med. 1995; 208:124-30.
118. Larocca LM, Piantelli M, Leone G, Sica S, Teofili L, Benedetti Panici P, Scambia G, Mancuso S, Capelli A, Ranelletti FO. Type II oestrogen binding sites in acute lymphoid and myeloid leukaemias: growth inhibitory effect of oestrogen and flavonoids. Br. J. Haematol. 1990; 75:489-95.
119. Post JFM, Varma RS. Growth inhibitory effects of bioflavonoids and related compounds on human leukemic CEM-C1 and CEM-C7 cells. Cancer Lett. 1992; 67:207-13.
120. Traganos F, Ardelt B, Halko N, Bruno S, Darzynkiewicz Z. Effécts of genistein on the growth and cell cycle progression of normal human lymphocyte and human leukemic MOLT 4 and HL60 cells. Cancer Res. 1992; 52:6200-8.
121. Castillo MH, Perkins E, Campbell JH, Doerr R, Hassett JM, Kandaswami C, Middleton E. The effects of the bioflavonoid quercetin on squamous cell carcinoma of head and neck origin. Am. J. Surg. 1989; 158:351-5.
122. Kandaswami C, Perkins E, Soloniuk DS, Drzewiecki G, Middleton E. Ascorbic acid-enhanced antiproliferative effect of flavonoids on squamous cell carcinoma in vitro. Anticancer Drugs 1993; 4:91-6.
123. Yoshida M, Sakai T, Hosokawa N, Marui N, Matsumoto K, Fujioka A, Nishino H, Aoike A. The effect of quercetin on cell cycle progression and growth of human gastric cancer cells. FEBS Lett. 1990; 260:10-3.
124. 2-M. Cancer Res. 1993; 53:1328-31.
125. Hosokawa N, Hosokawa Y, Sakai T, Yoshida M, Marui N, Nishino H, Kawai K, Aoike A. Inhibitory effect of quercetin on the synthesis of a possibly cell-cycle-related 17-kDa protein, in human colon cancer cells. Int. J. Cancer 1990a; 45:1119-24.
126. Ranelletti FO, Ricci R, Larocca LM, Maggiano N, Capelli A, Scambia G, Benedetti-Panici P, Mancuso S, Rumi C, Piantelli M. Growth-inhibitory effect of quercetin and presence of type-II estrogen-binding sites in human colon-cancer cell lines and primary colorectal tumors. Int. J. Cancer 1992; 50:486-92.
127. Agullo G, Garnet L, Besson C, Demigné C, Rémésy C. Quercetin exerts a preferential cytotoxic effect on active dividing colon carcinoma HT29 and Caco-2 cells. Cancer Lett. 1994; 87:55-63.
128. Scambia G, Ranelletti FO, Benedetti-Panici P, Piantelli M, Bonanno G, De Vincenzo R, Ferrandina G, Pierelli L, Capelli A, Mancuso S. Quercetin inhibits the growth of a multidrug-resistant estrogen-receptor-negative MCF-7 human breast-cancer cell line expressing type II estrogen-binding sites. Cancer Chemother. Pharmacol. 1991; 28:255-8.
129. Scambia G, Ranelletti FO, Benedetti panici P, Piantelli M, Bonanno G, De Vincenzo R, Ferrandina G, Rumi C, Larocca LM, Mancuso S. Inhibitory effect of quercetin on OVCA 433 cells and presence of type II oestrogen binding sites in primary ovarian tumours and cultured cells. Br. J. Cancer 1990a; 62:942-6.
130. Peterson G, Barnes S. Genistein and biochanin A inhibit the growth of human prostate cancer cells but not epidermal growth factor receptor tyrosine autophosphorylation. Prostate 1993; 22:335-45.
131. 1 phase of the cell cycle. Cancer Res. 1992; 52:6676-81.
132. Larocca LM, Teofili L, Leone G, Sica S, Pierelli L, Menichella G, Scambia G, Benedetti Panici P, Ricci R, Piantelli M, Ranelletti FO. Antiproliferative activity of quercetin on normal bone marrow and leukaemic progenitors. Br. J. Haematol. 1991; 79:562-6.
133. Kandaswami C, Perkins E, Drzewiecki G, Soloniuk DS, Middleton E. Differential inhibition of proliferation of human squamous cell carcinoma, gliosarcoma and embryonic fibroblast-like lung cells in culture by plant flavonoids. Anticancer Drugs 1992; 3:525-30.
134. Kondo K, Tsuneizumi K, Watanabe T, Oishi M. Induction of in vitro differentiation of mouse embryonal carcinoma (F9) cells by inhibitors of topoisomerases. Cancer Res. 1991; 51:5398-404.
135. Jing Y, Nakaya K, Han R. Differentiation of promyelocytic leukemia cells HL-60 induced by daidzein in vitro and in vivo. Anticancer Res. 1993; 13:1049-54.
136. Constantinou A, Huberman E. Genistein as an inducer of tumor cell differenciation: possible mechanisms of action. Proc. Soc. Exp. Biol. Med. 1995; 208:109-15.
137. Suolinna EM, Buchsbaum RN, Racker E. The effect of flavonoids on aerobic glycolysis and growth of tumor cells. Cancer Res. 1975; 35:1865-72.
138. Graziani Y, Chayoth R. Elevation of cyclic AMP level in ehrlich ascites tumor cells by quercetin. Biochem. Pharmacol. 1977; 26:1259-61.
139. Belt JA, Thomas JA, Buchsbaum RN, Racker E. Inhibition of lactate transport and glycolysis in Ehrlich ascites tumor cells by bioflavonoids. Biochemistry 1979; 18:3506-11.
140. 2+)-ATPase of sarcoplasmic reticulum. J. Biol. Chem. 1981; 256:887-92.
141. +-ATPase: aspects of structure-activity relationship and action mechanism. Life Sci. 1989; 45:1111-7.
142. Grisolia S, Rubio V, Feijoo B, Mendelson J. Inhibition of lactic deshydrogenase and of pyruvate kinase by low concentrations of quercetin. Physiol. Chem. Physics 1975; 7:473-5.
143. Levy J, Teuerstein I, Marbach M, Radian S, Sharoni Y. Tyrosine protein kinase activity in the DMBA-induced rat mammary tumor: inhibition by quercetin. Biochem. Biophys. Res. Commun. 1984; 123:1227-33.
144. v-src kinase activities. In: Cody V, Middleton E, Harborne JB, eds. Plant Flavonoids in Biology and Medicine. Biochemical Pharmacological and Structure Activity Relationships. New York: Alan R. Liss, Inc., 1986: 301-13.
145. Akiyama T, Ishida J, Nakagawa S, Ogawara H, Watanabe SI, Itoh N, Shibuya M, Fukami Y. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J. Biol. Chem. 1987; 262:5592-5.
146. Peterson G. Evaluation of the biochemical targets of genistein in tumor cells. J. Nutr. 1995; 125:784S-9S.
147. Linassier CM, Pierre M, Pecq JBL, Pierre J. Mechanisms of action in NIH 3T3 cells of genistein, an inhibitor of EGF receptor tyrosine kinase activity. Biochem. Pharmacol. 1990; 39:187-93.
148. Giri U, Sharma SD, Abdulla M, Athar M. Evidence that in situ generated reactive oxygen species act as a potent stage I tumor promoter in mouse skin. Biochem. Biophys. Res. Commun. 1995; 209: 698-705.
149. Gschwendt M, Horn F, Kittstein W, Fürstenberger G, Besemfelder E, Marks F. Calcium and phospholipid-dependent protein kinase activity in mouse epidermis cytosol. Stimulation by complete and incomplete tumor promoters and inhibition by various compounds. Biochem. Biophys. Res. commun. 1984; 124:63-8.
150. Welton AF, Tobias LD, Friedler-Nagy C, Anderson W, Hope W, Meyers K, Coffey JW. Effect of flavonoids on arachidonic acid metabolism. In: Cody V, Middleton E, Harborne JB, eds. Plant Flavonoids in Biology and Medicine. Biochemical Pharmacological and Structure Activity Relationships. New York: Alan R. Liss, Inc., 1986: 231-42.
151. Sharoni Y, Teuerstein I, Levy J. Phosphoinositide phosphorylation precedes growth in rat mammary tumors. Biochem. Biophys. Res. Commun. 1986; 134:876-82.
152. -γ1 associates with viral and cellular src kinases. J. Biol. Chem. 1993; 268:10754-9.
153. Okano Y, Mizuno K, Osada S, Nakamura T, Nozawa Y. Tyrosine phosphorylation of phospholipase Cy in c-met/HGF receptor-stimulated hepatocytes: comparison with HepG2 hepatocarcinoma cells. Biochem. Biophys. Res. Commun. 1993; 190:842-8.
154. Srivastava AK. Inhibition of phosphorylase kinase, and tyrosine protein kinase activities by quercetin. Biochem. Biophys. Res. Commun. 1985; 131:1-5.
155. Ferriola PC, Cody V, Middleton E. Protein kinase C inhibition by plant flavonoids. Biochem. Pharmacol. 1989; 38:1617-24.
156. Jinsart W, Ternai B, Polya GM. Inhibition of rat liver cyclic-AMP-dependent protein kinase by flavonoids. Biol. Chem. Hoppe-Seyler 1992; 373:205-11.
157. Avila MA, Velasco JA, Cansado J, Notario V. Quercetin mediates the down-regulation of mutant p53 in the human breast cancer cell line MDA-MB468. Cancer Res. 1994; 54:2424-8.
158. Hollstein M, Sidransky D, Vogelstein B, Harris CC. P53 mutations in human cancers. Science 1991; 253:49-53.
159. Clark JH, Hardin JW, Upchurch S. Heterogeneity of estrogen binding sites in the cytosol of the rat uterus. J. Biol. Chem. 1978; 253: 7630-4.
160. Markaverich BM, Clark JH. Two binding sites for estradiol in rat uterine nuclei: relationship to uterotrophic response. Endocrinology 1979; 105:1458-62.
161. Piantelli M, Ricci R, Larocca LM, Rinelli A, Capelli A, Rizzo S, Scambia G, Ranelletti FO. Type II oestrogen binding sites in human colorectal carcinoma. J. Clin. Pathol. 1990; 43:1004-6.
162. Teofili L, Pierelli L, Iovino MS, Leone G, Scambia G, De Vincenzo R, Benedetti-Panici P, Menichella G, Macri E, Piantelli M, Ranelletti FO, Larocca LM. The combination of quercetin and cytosine arabinoside synergistically inhibits leukemic cell growth. Leuk. Res. 1992; 16:497-503.
163. 3H]estradiol binding to nuclear type II estrogen binding sites in normal and malignant tissues. Cancer Res. 1984; 44:1575-9.
164. Markaverich BM, Gregory RR, Alejandro MA, Kittrell FS, Medina D, Clark JH, Varma M, Varma RS. Methyl p-hydroxyphenyllactate and nuclear type II binding sites in malignant cells: metabolic fate and mammary tumor growth. Cancer Res. 1990; 50:1470-8.
165. Scambia G, Ranelletti FO, Benedetti-Panici P, Piantelli M, De Vincenzo R, Ferrandina G, Bonanno G, Capelli A, Mancuso S. Quercetin induces type-II estrogen-binding sites in estrogen-receptor-negative (MDA-MB231) and estrogen-receptor-positive (MCF-7)human breast-cancer cell lines. Int. J. Cancer 1993; 54:462-6.
166. Markaverich BM, Roberts RR, Alejandro MA, Johnson GA, Middleditch BS, Clark JH Bioflavonoid interaction with rat uterine type II binding sites and cell growth inhibition. J. Steroid Biochem. 1988; 30:71-8.
167. Scambia G, Ranelletti FO, Benedetti Panici P, De Vincenzo R, Bonanno G, Ferrandina G, Piantelli M, Mancuso S. Quercetin and hyperthermia produce a synergistic inhibitory effect on primary human ovarian cancer cells. Int. J. Oncology 1992; 1:299-302.
168. Kim JH, Kim SH, Alfieri AA, Young CW. Quercetin, an inhibitor of lactate transport and a hyperthermic sensitizer of HeLa cells. Cancer Res. 1984; 44:102-6.
169. Hosokawa N, Hirayoshi K, Nakai A, Hosokawa Y, Marui N, Yoshida M, Sakai T, Nishino H, Aoike A, Kawai K, Nagata K. Flavonoids inhibit the expression of heat shock proteins. Cell Struct. Funct. 1990b; 15:393-401.
170. Nagai N, Nakai A, Nagata K. Quercetin suppresses heat shock response by down regulation of HSF1. Biochem. Biophys. Res. Commun. 1995; 208:1099-105.
171. Kantengwa S, Polla BS. Flavonoids, but not protein kinase C inhibitors, prevent stress protein synthesis during erythrophagocytosis. Biochem. Biophys. Res. Commun. 1991; 180:308-14.
172. Burdon RH. Heat shock and the heat shock proteins. Biochem. J. 1986; 240:313-24.
173. Elia G, Santoro MG. Regulation of heat shock protein synthesis by quercetin in human erythroleukaemia cells. Biochem. J. 1994; 300:201-9.
174. Hofmann J, Fiebig HH, Winterhalter BR, Berger DP, Grunicke H. Enhancement of the antiproliferative activity of cis-diamminedichloroplatinum(II) by quercetin. Int. J. Cancer 1990; 45:536-9.
175. Scambia G, Ranelletti FO, Benedetti Panici P, Bonanno G, De Vincenzo R, Piantelli M, Mancuso S. Synergistic antiproliferative activity of quercetin and cisplatin on ovarian cancer cell growth. Anticancer Drugs 1990b; 1:45-8.
176. Hoffman R, Graham L, Newlands ES. Enhanced anti-proliferative action of busulphan by quercetin on the human leukaemia cell line K562. Br. J. Cancer 1989; 59:347-8.
177. Wiltrout RH, Hornung RL Natural products as antitumor agents: direct versus indirect mechanisms of activity of flavonoids. J. Natl. Cancer Inst. 1988; 80:220-2.
178. Gabor M. Anti-inflammatory and anti-allergic properties of flavonoids. In: Cody V, Middleton E, Harborne JB, eds. Plant Flavonoids in Biology and Medicine. Biochemical Pharmacological and Structure Activity Relationships. New York: Alan R. Liss, Inc., 1986: 471-80.
179. Selway JWT. Antiviral activity of flavones and flavans. In: Cody V, Middleton E, Harborne JB, eds. Plant Flavonoids in Biology and Medicine. Biochemical Pharmacological and Structure Activity Relationships. New York: Alan R. Liss, Inc., 1986: 521-36.
180. Middleton E, Kandaswami C. The impact of plant flavonoids on mammalian biology: Implications for immunity, inflammation and cancer. In: Harborne JB, ed. The Flavonoids: Advances in research since 1986. London: Chapman & Hall, 1993: 619-52.